Soluble programmed death-1 (sPD-1) as predictor of early surgical outcomes of paediatric cystic echinococcosis.
children
cystic echinococcosis
follow-up
post-surgical outcome
recP29
sPD-1
sPD-L1
Journal
Parasite immunology
ISSN: 1365-3024
Titre abrégé: Parasite Immunol
Pays: England
ID NLM: 7910948
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
11
08
2020
revised:
10
11
2020
accepted:
12
11
2020
pubmed:
19
11
2020
medline:
7
7
2021
entrez:
18
11
2020
Statut:
ppublish
Résumé
Following treatment, cystic echinococcosis (CE) exhibits a relatively high relapse rate. Here, we evaluated the value of soluble programmed death-1 (sPD-1), sPD-1 ligand (sPD-L1) and anti-recP29 antibody concentrations, as predictors of early surgical treatment outcomes in young CE-affected patients. This prospective study included 59 Tunisian children (177 plasmas), where CE was surgically treated and monitored for 3 post-operative years. Based on CE post-surgical development, patients were clustered into a 'No relapsed' CE (NRCE; n = 39) and a 'Relapsed' CE (RCE; n = 20) group. Plasma levels of sPD-1, sPD-L1 and anti-recP29 IgG were measured using ELISA. In the NRCE group, sPD-1, sPD-L1 and anti-recP29 IgG concentrations were significantly lower at D365 than at D30. By contrast, in the RCE group, no significant difference was observed between D0, D30 and D365. When considering individual variations, the probability to be 'relapse-free' was 67% and 73% when anti-recP29 IgG and sPD-L1 level, respectively, decreased between D30 and D365. The probability to be 'relapse-free' was 86% when the sPD-1 level decreased between D30 and D365 (P = .003; chi-square test). sPD-1 may be a useful biomaker for the early evaluation of surgical procedure efficacy in paediatric CE cases.
Substances chimiques
B7-H1 Antigen
0
Biomarkers
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12809Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Craig P, Mastin A, van Kesteren F, Boufana B. Echinococcus granulosus: epidemiology and state-of-the-art of diagnostics in animals. Vet Parasitol. 2015;213(3-4):132-148.
Oudni-M'rad M, Cabaret J, M'Rad S, et al. Genetic relationship between the Echinococcus granulosus sensu stricto cysts located in lung and liver of hosts. Infect Genet Evol: J Mol Epidemiol Evol Genet Infect Dis. 2016;44:356-360.
Craig PS, Larrieu E. Control of cystic echinococcosis/hydatidosis: 1863-2002. Adv Parasitol. 2006;61:443-508.
WHO/Department of control of neglected tropical diseases. Ending the Neglect to Attain the Sustainable Development Goals: A Road Map for Neglected Tropical Diseases 2021-2030. Geneva [Internet]; 2020. https://www.who.int/neglected_diseases/RevisedDraftNTDRoad_map2030v1.1.pdf?ua=1 https://www.who.int/neglected_diseases/resources/who-ucn-ntd-2020.01/en/
Budke CM, Carabin H, Ndimubanzi PC, et al. A systematic review of the literature on cystic echinococcosis frequency worldwide and its associated clinical manifestations. Am J Trop Med Hygiene. 2013;88(6):1011-1027.
Budke CM, Deplazes P, Torgerson PR. Global socioeconomic impact of cystic echinococcosis. Emerg Infect Dis. 2006;12(2):296-303.
Torgerson PR, Keller K, Magnotta M, Ragland N. The global burden of alveolar echinococcosis. PLoS Negl Trop Dis. 2010;4(6):e722.
Chahed MK, Bellali H, Touinsi H, et al. Distribution of surgical hydatidosis in Tunisia, results of 2001-2005 study and trends between 1977 and 2005. Arch Inst Pasteur Tunis. 2010;87(1-2):43-52.
Ksia A, Fredj MB, Zouaoui A, et al. Capitonnage seems better in childhood pulmonary hydatid cyst surgery. J Pediatr Surg. 2020;55(4):752-755.
Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114(1):1-16.
Piccoli L, Tamarozzi F, Cattaneo F, et al. Long-term sonographic and serological follow-up of inactive echinococcal cysts of the liver: hints for a “watch-and-wait” approach. PLoS Negl Trop Dis. 2014;8(8):e3057.
Ben Nouir N, Gianinazzi C, Gorcii M, et al. Isolation and molecular characterization of recombinant Echinococcus granulosus P29 protein (recP29) and its assessment for the post-surgical serological follow-up of human cystic echinococcosis in young patients. Trans R Soc Trop Med Hyg. 2009;103(4):355-364.
Chahed MK, Bellali H, Ben Alaya N, Aoun K, Zouari B. High risk areas for echinococcosis-hydatidosis in Tunisia. Tunis Med. 2015;93(1):33-37.
Siles-Lucas M, Casulli A, Conraths FJ, Muller N. Laboratory diagnosis of Echinococcus spp. in human patients and infected animals. Adv Parasitol. 2017;96:159-257.
Stojkovic M, Adt HM, Rosenberger K, et al. Follow-up of surgically treated patients with cystic echinococcosis: can novel recombinant antigens compete with imaging? Analysis of a patient cohort. Trop Med Int Health. 2017;22(5):614-621.
Boubaker G, Gottstein B, Hemphill A, Babba H, Spiliotis M. Echinococcus P29 antigen: molecular characterization and implication on post-surgery follow-up of CE patients infected with different species of the Echinococcus granulosus complex. PLoS One. 2014;9(5):e98357.
Hernandez-Gonzalez A, Santivanez S, Garcia HH, et al. Improved serodiagnosis of cystic echinococcosis using the new recombinant 2B2t antigen. PLoS Negl Trop Dis. 2012;6(7):e1714.
Hernandez-Gonzalez A, Sanchez-Ovejero C, Manzano-Roman R, et al. Evaluation of the recombinant antigens B2t and 2B2t, compared with hydatid fluid, in IgG-ELISA and immunostrips for the diagnosis and follow up of CE patients. PLoS Negl Trop Dis. 2018;12(9):e0006741.
Hernandez-Gonzalez A, Muro A, Barrera I, Ramos G, Orduna A, Siles-Lucas M. Usefulness of four different Echinococcus granulosus recombinant antigens for serodiagnosis of unilocular hydatid disease (UHD) and postsurgical follow-up of patients treated for UHD. Clin Vaccine Immunol: CVI. 2008;15(1):147-153.
Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. 2018;18(2):91-104.
Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550.
Gu D, Ao X, Yang Y, Chen Z, Xu X. Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer. 2018;6(1):132.
Shen H, Ji Y, Zhou D, et al. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis. Hematology (Amsterdam, Netherlands). 2019;24(1):392-398.
Chang B, Huang T, Wei H, et al. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol Immunother: CII. 2019;68(3):353-363.
Behairy OG, Behiry EG, El Defrawy MS, El Adly AN. Diagnostic value of soluble programmed cell death protein-1 in type-1 autoimmune hepatitis in Egyptian children. Scand J Clin Lab Invest. 2020;80(1):59-65.
Zhou L, Li X, Huang X, Chen L, Gu L, Huang Y. Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B. J Viral Hepatitis. 2019;26(7):795-802.
Leon-Flores A, Del Rio Estrada PM, Alvarez-Garcia LX, Piten-Isidro E, Reyes-Teran G. Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1(+) individuals. Immunol Lett. 2018;203:70-79.
Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. 2017;8(57):97671-97682.
Habib S, El Andaloussi A, Elmasry K, et al. PDL-1 blockade prevents T cell exhaustion, inhibits autophagy, and promotes clearance of Leishmania donovani. Infect Immun. 2018;86(6):1-14. https://doi.org/10.1128/IAI.00019-18
Bhadra R, Gigley JP, Weiss LM, Khan IA. Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade. Proc Natl Acad Sci USA. 2011;108(22):9196-9201.
Terrazas LI, Montero D, Terrazas CA, Reyes JL, Rodríguez-Sosa M. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis. Int J Parasitol. 2005;35(13):1349-1358.
Wang J, Jebbawi F, Bellanger AP, Beldi G, Millon L, Gottstein B. Immunotherapy of alveolar echinococcosis via PD-1/PD-L1 immune checkpoint blockade in mice. Parasite Immunol. 2018;40(12):e12596.
La X, Zhang F, Li Y, et al. Upregulation of PD-1 on CD4⁺CD25⁺ T cells is associated with immunosuppression in liver of mice infected with Echinococcus multilocularis. Int Immunopharmacol. 2015;26(2):357-366.
Li Y, Xiao Y, Su M, et al. Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis. Exp Ther Med. 2016;11(1):251-256.
International classification of ultrasound images in cystic echinococcosis for application in clinical and field epidemiological settings. Acta Trop. 2003;85(2):253-261.
Hosch W, Junghanss T, Stojkovic M, et al. Metabolic viability assessment of cystic echinococcosis using high-field 1H MRS of cyst contents. NMR Biomed. 2008;21(7):734-754.
Deplazes P, Rinaldi L, Alvarez Rojas CA, et al. Global distribution of alveolar and cystic echinococcosis. Adv Parasitol. 2017;95:315-493.
Craig PS, Hegglin D, Lightowlers MW, Torgerson PR, Wang Q. Chapter two - Echinococcosis: control and prevention. In: Thompson RCA, Deplazes P, Lymbery AJ, editors. Advances in Parasitology, Vol. 96. Cambridge: Academic Press; 2017:55-158. https://doi.org/10.1016/bs.apar.2016.09.002.
Kern P, Menezes da Silva A, Akhan O, et al. The echinococcoses: diagnosis, clinical management and burden of disease. Adv Parasitol. 2017;96:259-369.
Tamarozzi F, Mariconti M, Neumayr A, Brunetti E. The intermediate host immune response in cystic echinococcosis. Parasite Immunol. 2016;38(3):170-181.
Gottstein B, Soboslay P, Ortona E, Wang J, Siracusano A, Vuitton D. Immunology of alveolar and cystic echinococcosis (AE and CE). Adv Parasitol. 2017;96:1-54.
González G, Spinelli P, Lorenzo C, et al. Molecular characterization of P-29, a metacestode-specific component of Echinococcus granulosus which is immunologically related to, but distinct from, antigen 5. Mol Biochem Parasitol. 2000;105(2):177-184.
Kapan M, Kapan S, Goksoy E, Perek S, Kol E. Postoperative recurrence in hepatic hydatid disease. J Gastrointest Surg: Off J Soc Surg Alimentary Tract. 2006;10(5):734-739.
Sielaff TD, Taylor B, Langer B. Recurrence of hydatid disease. World J Surg. 2001;25(1):83-86.
Manzano-Roman R, Sanchez-Ovejero C, Hernandez-Gonzalez A, Casulli A, Siles-Lucas M. Serological diagnosis and follow-up of human cystic echinococcosis: a new hope for the future? Biomed Res Int. 2015;2015:428205.